MENU
+Compare
AUPH
Stock ticker: NASDAQ
AS OF
Jul 18 closing price
Price
$8.63
Change
-$0.44 (-4.85%)
Capitalization
1.17B

AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more

Industry: #Biotechnology
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AUPH with price predictions
Jul 18, 2025

AUPH's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for AUPH moved out of overbought territory on June 30, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AUPH entered a downward trend on June 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 09, 2025. You may want to consider a long position or call options on AUPH as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on July 10, 2025. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

AUPH moved above its 50-day moving average on July 09, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on July 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.330) is normal, around the industry mean (18.109). P/E Ratio (31.963) is within average values for comparable stocks, (58.647). AUPH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (5.058) is also within normal values, averaging (270.773).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AUPH is expected to report earnings to fall 10.00% to 14 cents per share on July 31

Aurinia Pharmaceuticals AUPH Stock Earnings Reports
Q2'25
Est.
$0.14
Q1'25
Beat
by $0.05
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
Q2'24
Est.
$0.01
The last earnings report on May 12 showed earnings per share of 15 cents, beating the estimate of 10 cents. With 2.01M shares outstanding, the current market capitalization sits at 1.17B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
14315 118 Avenue
Phone
+1 250 708-4272
Employees
300
Web
https://www.auriniapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DIFEX12.300.02
+0.16%
MFS Diversified Income R2
MGNDX52.020.04
+0.08%
Praxis Growth Index A
NBPIX48.25-0.07
-0.14%
Neuberger Berman Large Cap Value Instl
RFISX17.17-0.11
-0.64%
Ranger Small Cap Institutional
HSCSX24.75-0.21
-0.84%
Homestead Small Company Stock

AUPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with ROIV. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-4.85%
ROIV - AUPH
38%
Loosely correlated
-1.80%
SHJBF - AUPH
38%
Loosely correlated
N/A
CRNX - AUPH
37%
Loosely correlated
-5.78%
QURE - AUPH
37%
Loosely correlated
-1.38%
NAMS - AUPH
36%
Loosely correlated
+1.00%
More